ctDNA

Questions discussed in this category

Why does NCCN still not recommend using circulating tumor cells to guide adjuvant chemotherapy in stage II colon cancer when colon cancer experts are currently embracing the practice?

1 Answer available

How do you approach early-stage breast cancer patients who are asking for ctDNA or tumor marker surveillance (or previously receiving these with another provider) when these are not part of the NCCN or ASCO guidelines?

2 Answers available

For patients with resected colon cancer, to what extent would you adapt adjuvant chemotherapy if ctDNA results don't correspond with your initial treatment recommendation?

3 Answers available

How would positive ctDNA results after 12 cycles of adjuvant FOLFOX affect your management for patients with colon cancer?

4 Answers available

How, if at all, are you employing ctDNA in the management of patients with colon cancer?

1 Answer available

Papers discussed in this category

N Engl J Med, 2022 Jun 04

Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer.

JCO precision oncology, 2022 Jul

Reply to F. Dayyani et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023 May 15

Oxaliplatin in Adjuvant Colorectal Cancer: Is There a Role in Older Patients?

JAMA network open, 2022 Mar 01

Evaluation of Comparative Surveillance Strategies of Circulating Tumor DNA, Imaging, and Carcinoembryonic Antigen Levels in Patients With Resected Colorectal Cancer.

Related Topics